The Cancer Letter

Inside information on cancer research and drug development

Guest Editorial

How the Lung-MAP Clinical Trial is Responding to Rapidly Changing Science

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

When the Lung Master Protocol clinical trial (Lung-MAP or S1400) (1) was launched in June 2014, the goal of this first-of-its kind trial was simple: find effective treatments for seriously ill patients suffering from a specific type of lung cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Roy S. Herbst
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
David Gandara
Co-principal investigator, Lung-MAP trial; Director, Thoracic Oncology Program, University of California, Davis
Vassiliki Papadimitrakopoulou
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

Cancer History ProjectGuest Editorial

At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
By Katerina A. Politi and Roy S. Herbst
Byline
Roy S. Herbst
Co-principal investigator, Lung-MAP trial
Chief of Medical Oncology, associate director for translational research, Yale Cancer Center
David Gandara
Co-principal investigator, Lung-MAP trial; Director, Thoracic Oncology Program, University of California, Davis
Vassiliki Papadimitrakopoulou
Co-principal investigator, member of oversight and drug selection committees, Lung-MAP trial; professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account